4D Molecular Therapeutics, Inc. Common Stock (FDMT)
4D Molecular Therapeutics, Inc. (FDMT) is a biotechnology company focused on developing targeted gene therapies for various genetic and acquired diseases. Utilizing its proprietary vector platform, 4DMT aims to deliver precise and durable treatments through innovative vector design and delivery methods. The company emphasizes leveraging advanced genetic engineering technologies to create therapies with enhanced specificity and reduced immunogenicity.
Company News
GenVivo appointed Dr. Noriyuki Kasahara as Chief Scientific Officer to advance its genetic therapy platform for cancer treatment, leveraging his extensive experience in gene therapy and vector technology research.
4D Molecular Therapeutics reported Q2 2025 financial results with $15 million revenue, exceeding estimates, driven by collaboration income. The company advanced its gene therapy programs for retinal and respiratory diseases, with promising clinical trial progress and a workforce reduction to manage expenses.
The Schall Law Firm is investigating potential securities fraud claims against 4D Molecular Therapeutics, Inc. after the company's interim Phase 2 study results for its drug Intravitreal 4D-150 caused the stock to drop over 35% on the same day.
4D Molecular Therapeutics' stock price dropped after the company reported disappointing results from a mid-stage clinical trial for one of its gene therapy candidates.
4D Molecular Therapeutics (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.